Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease

IDrugs

Volumn 13, Issue 12, 2010, Pages 890-899

  Okamura, Nobuyuki ^a   Yanai, Kazuhiko ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AV 138; AV 138 F 18; AV 144; AV 144 F 18; AV 19; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GE 067; PF 4494700; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; UNCLASSIFIED DRUG; 4 (2 (6 (2 (2 (2 FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN 3 YL)VINYL) N METHYLBENZAMIDE; 4-(2-(6-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)VINYL)-N-METHYLBENZAMIDE; ANILINE DERIVATIVE; DIAGNOSTIC AGENT; ETHYLENE GLYCOL DERIVATIVE; FLUORINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BLOOD BRAIN BARRIER; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; FRONTOTEMPORAL DEMENTIA; HUMAN; IMAGE QUALITY; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; PATENT; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; REPRODUCIBILITY; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VITAL SIGN; ANIMAL; BRAIN; MOLECULAR IMAGING; REVIEW; SCINTISCANNING;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; ANIMALS; BRAIN; ETHYLENE GLYCOLS; FLUORINE RADIOISOTOPES; HUMANS; MOLECULAR IMAGING; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79952742715     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Localization of neurofbrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR AM J GERIATR PSYCHIAT 2002 10 1 24-35 (Pubitemid 34052900)
2. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B et al ANN NEUROL 2004 55 3 306-319 (Pubitemid 38269583)
3. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Zhang W, Oya S, Kung M-P, Hou C, Maier DL, Kung HF NUCL MED BIOL 2005 32 8 799-809 (Pubitemid 41505313)
4. Avid announces results of AV-1 molecular imaging agent for Alzheimer's disease presented at AD/PD meeting. Avid Radiopharmaceuticals Inc PRESS RELEASE 2007 March 19
5. Avid Radiopharmaceuticals: Pipeline. Avid Radiopharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2005 December 31
6. 18F PET amyloid-imaging agents: Preclinical to clinical correlations. Skovronsky DM, Coleman R, Frey K, Garg P, Ichise M, Lowe V, Mintun M, Wong D, Kung H J NUCL MED 2008 49 Suppl 1 Abs 133
7. Quantitative comparison of three novel F-labeled ligands for PET imaging of brain amyloid-β plaques in Alzheimer's disease. Ichise M, Plett SA, Joshi A, Stern Y, Van Heertum R, Lowe V, Coleman E, Mintun M, Wong D, Kung H J NUCL MED 2008 49 Suppl 1 Abs 923
8. Radiation dosimetry of F18-AV-45 measured by PET/CT in humans. Adler LP, Wolodzko J, Stabin M, McNelis T, Gammage L, Joshi A J NUCL MED 2008 49 Suppl 1 Abs 1211
9. F-18 AV-45 (forpiramine F-18): A PET imaging agent for mapping β-amyloid plaques in the brain. Choi SR, Skovronsky D, Hefti F, Carpenter A, Golding G, Zhuang ZP, Lim N, Benedum T, Zhang W, Kung H J NUCL MED 2009 50 Suppl 2 Abs 1190
10. Florpiramine F 18 (AV-45) is an amyloid plaque-selective PET imaging agent. Choi SR, Skovronsky D, Hefti F, Honson N, Kuret J, Kung H J NUCL MED 2009 50 Suppl 2 Abs 1202
11. Test-retest reproducibility of forpiramine F 18 (18F-AV-45) PET amyloid imaging. Pontecorvo M, Clark C, Joshi A, Jennings D, Sadowsky C, Safrstein B, Lowrey M, Saha K, Skovronsky D J NUCL MED 2009 50 Suppl 2 Abs 1251
12. Semi-quantitative visual rating of forpiramine F 18 (18F-AV-45) PET scans. Skovronsky D, Mintun M, Carpenter A, Clark C, Joshi A, Hefti F, Pontecorvo M J NUCL MED 2009 50 Suppl 2 Abs 425
13. Relationship between regional amyloid levels and cognitive performance in healthy controls, MCI subjects, and patients with AD: Phase II results from a forpiramine F18 PET imaging study. Doraiswamy PM, Farmer M, Holub R, Johnson K, Reiman EM, Sadowsky C, Safrstein B, Spicer K, Carpenter A, Clark CM, Joshi A ALZHEIMER DEMENT 2009 5 4, Suppl Abs O1-01-03
14. PET imaging of β-amyloid with forpiramine F 18 (18F-AV-45); Preliminary results from a phase II study of cognitively normal elderly subjects, individuals with mild cognitive impairment, and patients with a clinical diagnosis of Alzheimer's disease. Sperling R, Johnson K, Pontecorvo MJ, Safrstein B, Farmer M, Holub R, Korn R, Spicer K, Doraiswamy M, Reiman EM, Joshi A et al ALZHEIMER DEMENT 2009 5 4 Suppl Abs P1-084
15. Eli Lilly-Q2 presentation. Eli Lilly & Co COMPANY PRESENTATION 2009 July 22
16. F-AV-45, an Aβ amyloid PET imaging ligand, binds protofbrillar Aβ aggregates. Conway KA, Skovronsky DM, Hefti FF SOC NEUROSCI ANN MEET 2009 39 18 October Abs 141.1/E22
17. Strong positive correlation of in vitro F-AV-45 binding with neuropathological data of amyloid plaque burden. Choi SR, Hefti FF, Skovronsky DM, Clark CC, Kung HF SOC NEUROSCI ANN MEET 2009 39 18 October Abs 141.8/E29
18. AstraZeneca development pipeline, 28 January 2010
19. AstraZeneca plc COMPANY WORLD WIDE WEB SITE 2010 January 28
20. F-18 stilbenes and styrylpyridines for PET imaging of Aβ plaques in Alzheimer's disease: A miniperspective. Kung HF, Choi SR, Qu WC, Zhang W, Skovronsky D J MED CHEM 2010 53 3 933-941
21. C-PiB PET assessment of change in fbrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S et al LANCET NEUROLOGY 2010 9 4 363-372
22. Positive interim results from phase III trial of amyloid imaging agent forbetapir F18 presented at American Academy of Neurology Annual Meeting. Avid Radiopharmaceuticals Inc PRESS RELEASE 2010 April 14
23. 18F-AV-45) PET imaging of β-amyloid plaques is highly correlated with histopathological assays at autopsy. Mintun M, Saha K, Fleisher A, Schneider J, Beach T, Bedell B, Clark C, Pontecorvo M, Skovronsky D J NUCL MED 2010 51 Suppl 2 Abs 387
24. Whole-body biodistribution and brain PET imaging with [F-18]AV-45, a novel amyloid imaging agent-A pilot study. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH, Yen TC et al NUCL MED BIOL 2010 37 4 497-508
25. Imaging of amyloid β in Alzheimer's disease with F-18-BAY94-9172, a novel PET tracer: Proof of mechanism. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL et al LANCET NEUROLOGY 2008 7 2 129-135
26. Preclinical properties of F-18-AV-45: A PET agent for a β plaques in the brain. Choi SR, Golding G, Zhuang ZP, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF J NUCL MED 2009 50 11 1887-1894
27. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand F-18-AV-45 (fobetapir F 18). Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye WG, Hilton J et al J NUCL MED 2010 51 6 913-920
28. In cognitively healthy and mildly impaired individuals forbetapir F 18 PET measures of amyloid deposition correlate with the degree of functional impairment assessed six months later. Doraiswamy PM, Coleman RE, Petrella JR, Sheldon F, Pontecorvo MJ, Hefti F, Carpenter A, Skovronsky DM, Clark CM NEUROLOGY 2010 74 9 Abs P04.076
29. Histopathological validation of amyloid imaging with forbetapir F 18 (F-18-AV-45) PET in an ongoing phase III prospective clinical study of subjects at the end of life. Fleisher AS, Schneider JA, Beach TG, Bedell B, Zehntner S, Gamez J, Sicuro F, Coeur C, Patel M, Sabbagh M, Clark CM et al NEUROLOGY 2010 74 9 Abs S24.001
30. A novel approach for semi-quantitative estimation of global amyloid uptake utilizing F-forbetapir (forbetapir F 18) and positron emission tomography. Saha K, Romanowicz G, Joshi A, Pontecorvo M, Burns J, Carpenter A, Skovronsky D J NUCL MED 2010 51 Suppl 2 Abs 53
31. Quantifcation of F-AV-45 (forbetapir) PET imaging in presence of brain atrophy: A comparison of manual and automatic approaches. Romanowicz G, Saha K, Joshi A, Pontecorvo M, Carpenter A, Skovronsky D J NUCL MED 2010 51 Abs 1291
32. Validation of a novel PET method for quantitation of amyloid pathology. Romanowicz G, Saha K, Krautkramer M, Joshi A, Pontecorvo M, Carpenter A, Skovronsky D J NUCL MED 2010 51 Suppl 2 Abs 570
33. A retrospective evaluation of PET scanner properties utilizing Brain Hoffman Phantom imaging for F-18-AV-45 study. Saha K, Romanowicz G, Joshi A, Pontecorvo M, Galette P, Carpenter A, Skovronsky D J NUCL MED 2010 51 Abs 1417
34. Medivation reports second quarter 2010 fnancial results and provides corporate update. Medivation Inc PRESS RELEASE 2010 August 09
35. Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trials. Eli Lilly & Co PRESS RELEASE 2010 August 17
36. F-18-futemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment a phase 2 trial. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L et al ANN NEUROL 2010 68 3 319-329
37. 18F-AV45 in frontotemporal dementia. Vardy ERLC, Hinz R, Langheinrich T, Snowden J, Gerhard A, Richardson AMT, Anton J, Brown GD, Neary D, Herholz K ALZHEIMER DEMENT 2010 6 4 Suppl Abs IC-P-085
38. 18F-AV-45) PET in a subject with Down's syndrome and Alzheimer's disease at the end of life. Sabbagh MN, Jacobson SA, Sue LI, Liebsack C, Charney AS, Beach TG ALZHEIMER DEMENT 2010 6 4 Suppl Abs IC-P-053
39. 18F-labeled A β amyloid imaging agent. Pontecorvo JM, Coleman RE, Doraiswamy M, Lowe V, Mintun M, Morris J, Petersen R, Rosenberg P, Ross J, Sadowsky C, Williamson J et al ALZHEIMER DEMENT 2008 4 4 Suppl Abs HT-01-02
40. Use of exploratory INDs in evaluation of F-labeled PET amyloid plaque imaging agents. Pontecorvo M, Carpenter A, Coleman RE, Frey K, Hefti F, Lowe V, Mintun M, Manchanda R, Wong D, Skovronsky D J NUCL MED 2008 49 Suppl 1 Abs 367
41. β-amyloid imaging utilizing F-AV-45-A technologist's perspective. Burns J, Skovronsky D, Pontecorvo M, Carpenter A, Galette P, Saha K, Joshi A, Romanowicz G, Ramirez J J NUCL MED 2010 51 Suppl 2 Abs 2021
42. In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand [1 F] AV-45. Wong D, Rosenberg P, Zhou Y, Kumar A, Ravert H, Brasic J, Ye W, Alexander M, Galecki J, Lyketsos C, Pontecorvo M, Skovronsky D J NUCL MED 2008 49 Suppl 1 Abs 925
43. A semiautomated method for quantifcation of F-labelled amyloid plaque imaging agents. Joshi A, Wolodzko J, Pontecorvo M, Skovronsky D J NUCL MED 2008 49 Suppl 1 Abs 933
44. A semiautomated method for quantifcation of F-labelled amyloid plaque imaging agents based on volume of interest and voxel-based statistical analyses. Joshi A, Skovronsky D, Pontecorvo M ALZHEIMER DEMENT 2008 4 4 Suppl Abs P2-025
45. 18F Aβ amyloid imaging agents. Pontecorvo M, Coleman RE, Doraiswamy M, Lowe V, Mintun M, Morris J, Petersen R, Rosenberg P, Ross J, Sadowsky C, Williamson J et al ALZHEIMER DEMENT 2008 4 4 Suppl Abs IC-P3-205
46. In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand [1 F] AV-45. Rosenberg PB, Zhou Y, Kumar A, Ravert HT, Brasic J, Ye W, Alexander M, Dannals RF, Galecki J, Lyketsos CG, Skovronsky D et al ALZHEIMER DEMENT 2008 4 4 Suppl Abs P1-284
47. Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (1 F-AV-45): Imaging to histopathologic correlations in an end-of-life human subject study. Clark CM, Schneider JA, Mintun MMA, Bedell BJ, Beach TG, Sadowsky CH, Doraiswamy PM, Gamez J, Sabbagh MN, Fleisher AS ALZHEIMER DEMENT 2010 6 4 Suppl Abs O1-02-03
48. 18F-AV-45) PET amyloid imaging predicts progression of cognitive impairment: A longitudinal clinical follow up study. Sperling RA, Doraiswamy PM, Johnson K, Reiman EM, Sabbagh MN, Sadowsky CH, Carpenter A, Clark CM, Flitter M, Pontecorvo MJ, Skovronsky DM ALZHEIMER DEMENT 2010 6 4 Suppl Abs O1-02-04
49. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Hardy J, Selkoe DJ SCIENCE 2002 297 5580 353-356 (Pubitemid 34790756)
50. Amyloid deposition is associated with impaired default network function in older persons without dementia. Sperling RA, LaViolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL et al NEURON 2009 63 2 178-188
51. Outcome measures in clinical trials on medicinal products for the treatment of dementia: A European regulatory perspective. Broich K INT PSYCHOGERIATR 2007 19 3 509-524 (Pubitemid 46707435)
52. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease. Truffnet P, Bordet R, Menard J, Round TN, Giens XXIV THERAPIE 2009 64 3 145-148
53. PET instrumentation: What are the limits? Budinger TF SEMIN NUCL MED 1998 28 3 247-267 (Pubitemid 28371218)
54. (E)-4-(2-(6-(2-(2-(2-([18F]-fuoroethoxy)ethoxy)ethoxy) pyridin-3-yl)vinyl)-N-methyl benzenamine. Bethesda (MD): National Center for Biotechnology Information (US) MOL IMAGING CONTRAST AGENT DATABASE 2010 February 11
55. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ NATURE 2002 416 6880 535-539 (Pubitemid 34288854)
56. The β-secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. Vassar R, Kovacs DM, Yan RQ, Wong PC J NEUROSCI 2009 29 41 12787-12794
57. Secretase inhibition and modulation for Alzheimer's disease. Wolfe MS CURR ALZHEIMER RES 2008 5 2 158-164 (Pubitemid 351536340)
58. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Price JL, Morris JC ANN NEUROL 1999 45 3 358-368 (Pubitemid 29120041)
59. 11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC NEUROLOGY 2006 67 3 446-452 (Pubitemid 44214969)
60. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA ARCH NEUROL 2009 66 12 1469-1475
61. F-18-labeled styrylpyridines as PET agents for amyloid plaque imaging. Zhang W, Kung MP, Oya S, Hou C, Kung HF NUCL MED BIOL 2007 34 1 89-97 (Pubitemid 46038150)
62. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF BRAIN RES 2004 1025 1-2 98-105 (Pubitemid 39359172)
63. 11C]SB-13 PET. Verhoeff NPLG, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S AM J GERIATR PSYCHIAT 2004 12 6 584-595 (Pubitemid 41031060)
64. PET of brain amyloid and tau in mild cognitive impairment. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM et al N ENGL J MED 2006 355 25 2652-2663 (Pubitemid 44969124)
65. Phase 1 study of the Pittsburgh compound B derivative F-futemetamol in healthy volunteers and patients with probable Alzheimer disease. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, Bormans G, Brooks DJ, Vandenberghe R J NUCL MED 2009 50 8 1251-1259
66. Florbetaben for β-amyloid brain PET in Alzheimer's disease: Results of a multicenter phase 2 trial. Sabri O, Gertz HJ, Dresel S, Heuser I, Bartenstein P, Burger K, Hiemeyer F, Reininger C, Seibyl J, Barthel H ALZHEIMER DEMENTIA 2010 6 Suppl 1 S70
67. Detection of amyloid in Alzheimer's disease with positron emission tomography using [1 C]AZD2184. Nyberg S, Jonhagen ME, Cselenyi Z, Halldin C, Julin P, Olsson H, Freund-Levi Y, Andersson J, Varnas K, Svensson S, Farde L EUR J NUCL MED MOL IMAGING 2009 36 11 1859-1863
68. Characterization of AZD4694, a novel fuorinated Aβ plaque neuroimaging PET radioligand. Jureus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnstrom P, Neelissen JAM, Sunnemark D, Farde L, Svensson SPS J NEUROCHEM 2010 114 3 784-794
69. 18F-AV-45: PET amyloid plaque imaging agent: Summary of development. Avid Radiopharmaceuticals Inc WEB SITE 2008 October 23
70. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Lemere CA, Masliah E NAT REV NEUROL 2010 6 2 108-119
71. The use of PET in Alzheimer disease. Nordberg A, Rinne JO, Kadir A, Langstrom B NAT REV NEUROL 2010 6 2 78-87
72. Dementia with Lewy bodies and Alzheimer disease: Neurodegenerative patterns characterized by DTI. Kantarci K, Avula R, Senjem ML, Samikoglu AR, Zhang B, Weigand SD, Przybelski SA, Edmonson HA, Vemuri P, Knopman DS, Ferman TJ et al NEUROLOGY 2010 74 22 1814-1821
73. Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Jellinger KA NEURODEGEN DIS 2008 5 3-4 118-121 (Pubitemid 351347827)
74. A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. Gibson GE, Shi QL J ALZHEIMER DIS 2010 20 S591-S607
75. Intracellular amyloid formation in muscle cells of Aβ-transgenic Caenorhabditis elegans: Determinants and physiological role in copper detoxifcation. Minniti AN, Rebolledo DL, Grez PM, Fadic R, Aldunate R, Volitakis I, Cherny RA, Opazo C, Masters C, Bush AI, Inestrosa NC MOL NEURODEGEN 2009 4 1 2
76. Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer's disease. Watson D, Castano E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES, Esh C, Luehrs DC, Stine WB, Rowse LM et al NEUROL RES 2005 27 8 869-881 (Pubitemid 41790274)
77. Paradigm shifts in Alzheimer's disease and other neuro degenerative disorders: The emerging role of oligomeric assemblies. Kirkitadze MD, Bitan G, Teplow DB J NEUROSCI RES 2002 69 5 567-577 (Pubitemid 34966869)
78. Lilly to acquire Avid Radiopharmaceuticals. Eli Lilly & Co PRESS RELEASE 2010 November 08
79. 2010 Alzheimer's disease facts and fgures. Alzheimer's Association ALZHEIMER DEMENT 2010 6 2 158-194
80. Imaging amyloid-β deposits in vivo. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT J CEREB BLOOD FLOW METAB 2002 22 9 1035-1041